Fibrinogen-Binding Peptide (TFA)

• UNSPSC Description:

  Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin[1].

• Target Antigen:

  Others

• Type:

  Peptides

• Related Pathways:

  Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/fibrinogen-binding-peptide-tfa.html

• Purity:

  99.32

• Solubility:

  H2O : 250 mg/mL (ultrasonic)

• Smiles:

  OC(C(F)(F)F)=O.C[C@@H](C(O)=O)NC([C@H]1N(C([C@H]([C@@H](C)CC)NC([C@H](CC2=CNC=N2)NC([C@H](CCC(O)=O)N)=O)=O)=O)CCC1)=O

• Molecular Weight:

  679.64

• References & Citations:

  [1]Gartner TK, et al. The peptide Glu-His-Ile-Pro-Ala binds fibrinogen and inhibits platelet aggregation and adhesion to fibrinogen and vitronectin. Proc Soc Exp Biol Med. 1991 Oct;198(1):649-55.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Clinical Information:

  No Development Reported